[
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know",
    "summary": "LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.",
    "url": "https://finnhub.io/api/news?id=88735d0fcb63a6cfb4e581b50d0e4d2668db1e9868c3c8c6eee0408602cc25e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759773420,
      "headline": "Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know",
      "id": 136989547,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.",
      "url": "https://finnhub.io/api/news?id=88735d0fcb63a6cfb4e581b50d0e4d2668db1e9868c3c8c6eee0408602cc25e5"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=d1a23f9a15f7872ac294e7c1283bde87d29cdea8fbb3b0e8bb2496db58ef51ec",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759768260,
      "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors",
      "id": 136995798,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=d1a23f9a15f7872ac294e7c1283bde87d29cdea8fbb3b0e8bb2496db58ef51ec"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?",
    "summary": "ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.",
    "url": "https://finnhub.io/api/news?id=5fcaf3a41fe0cdbdb83a5783564f188f7555554b2bd1b20dff5217998e180b68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759759860,
      "headline": "AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?",
      "id": 136989145,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.",
      "url": "https://finnhub.io/api/news?id=5fcaf3a41fe0cdbdb83a5783564f188f7555554b2bd1b20dff5217998e180b68"
    }
  },
  {
    "ts": null,
    "headline": "My Top 5 Biotech Stocks Big Pharma Could Buy Next",
    "summary": "Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.",
    "url": "https://finnhub.io/api/news?id=0615cc217ad0cd350a198a8133c50199b31af463e4f96ab378a062934e7cccc8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759757340,
      "headline": "My Top 5 Biotech Stocks Big Pharma Could Buy Next",
      "id": 136988239,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1146642361/image_1146642361.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.",
      "url": "https://finnhub.io/api/news?id=0615cc217ad0cd350a198a8133c50199b31af463e4f96ab378a062934e7cccc8"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk",
    "summary": "Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.",
    "url": "https://finnhub.io/api/news?id=f3d1e325c8979e5c256a781877a0e5161cf834c3f44fa173ef7dd8a98274314c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759755780,
      "headline": "Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk",
      "id": 136989147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.",
      "url": "https://finnhub.io/api/news?id=f3d1e325c8979e5c256a781877a0e5161cf834c3f44fa173ef7dd8a98274314c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor",
    "summary": "AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared to placebo for the treatment of upper limb essential tremor.",
    "url": "https://finnhub.io/api/news?id=9418d6b5514af09ccb61b36d6c7b4972870f7cf050fd59d5c5747e6ce3d2d7d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759755600,
      "headline": "AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor",
      "id": 136989240,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared to placebo for the treatment of upper limb essential tremor.",
      "url": "https://finnhub.io/api/news?id=9418d6b5514af09ccb61b36d6c7b4972870f7cf050fd59d5c5747e6ce3d2d7d7"
    }
  },
  {
    "ts": null,
    "headline": "How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results",
    "summary": "JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensured steady Q3 momentum.",
    "url": "https://finnhub.io/api/news?id=f3f2086007ac91191096aa6bdac656413082b1bbea04982fe6d38045151d30d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759753920,
      "headline": "How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results",
      "id": 136989208,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensured steady Q3 momentum.",
      "url": "https://finnhub.io/api/news?id=f3f2086007ac91191096aa6bdac656413082b1bbea04982fe6d38045151d30d0"
    }
  },
  {
    "ts": null,
    "headline": "REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD",
    "summary": "REGENXBIO Inc. (Nasdaq: RGNX) today announced the completion of enrollment in the ATMOSPHERE® and ASCENT® pivotal studies evaluating surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet age-related macular degeneration (wet AMD) using subretinal delivery.",
    "url": "https://finnhub.io/api/news?id=c6f3c7bf4b8611c528a1593857a041a86011ce642920c597466bfa15e1a340ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759748700,
      "headline": "REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD",
      "id": 136989243,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "REGENXBIO Inc. (Nasdaq: RGNX) today announced the completion of enrollment in the ATMOSPHERE® and ASCENT® pivotal studies evaluating surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet age-related macular degeneration (wet AMD) using subretinal delivery.",
      "url": "https://finnhub.io/api/news?id=c6f3c7bf4b8611c528a1593857a041a86011ce642920c597466bfa15e1a340ff"
    }
  }
]